Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2008 1
2009 2
2016 1
2017 1
2018 2
2019 1
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, Tummala H, Al Seraihi AFH, Alnajar J, Bewicke-Copley F, Armes H, Barnett M, Bloor A, Bödör C, Bowen D, Fenaux P, Green A, Hallahan A, Hjorth-Hansen H, Hossain U, Killick S, Lawson S, Layton M, Male AM, Marsh J, Mehta P, Mous R, Nomdedéu JF, Owen C, Pavlu J, Payne EM, Protheroe RE, Preudhomme C, Pujol-Moix N, Renneville A, Russell N, Saggar A, Sciuccati G, Taussig D, Toze CL, Uyttebroeck A, Vandenberghe P, Schlegelberger B, Ripperger T, Steinemann D, Wu J, Mason J, Page P, Akiki S, Reay K, Cavenagh JD, Plagnol V, Caceres JF, Fitzgibbon J, Dokal I. Rio-Machin A, et al. Among authors: mous r. Nat Commun. 2020 Feb 25;11(1):1044. doi: 10.1038/s41467-020-14829-5. Nat Commun. 2020. PMID: 32098966 Free PMC article.
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater AP. Niemann CU, et al. Among authors: mous r. Blood. 2020 Oct 7:blood.2020008608. doi: 10.1182/blood.2020008608. Online ahead of print. Blood. 2020. PMID: 33027809 No abstract available.
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T. Ruchlemer R, et al. Among authors: mous r. Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22. Mycoses. 2019. PMID: 31520441
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R, Ostrowski SR, Nasserinejad K, Kersting S, Dobber JA, Mattson M, Tran HTT, Levin MD, Mous R, Kater AP, Niemann CU. Svanberg R, et al. Among authors: mous r. Leuk Lymphoma. 2020 Dec;61(14):3422-3431. doi: 10.1080/10428194.2020.1811270. Epub 2020 Aug 31. Leuk Lymphoma. 2020. PMID: 32865439
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: mous r. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article.
(89) Zr-rituximab PET/CT to detect neurolymphomatosis.
de Jong A, Mous R, van Dongen GA, Hoekstra OS, Nievelstein RA, de Keizer B. de Jong A, et al. Among authors: mous r. Am J Hematol. 2016 Jun;91(6):649-50. doi: 10.1002/ajh.24328. Epub 2016 Apr 13. Am J Hematol. 2016. PMID: 26872558 Free article. No abstract available.
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC. Oostvogels R, et al. Among authors: mous r. Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6. Br J Haematol. 2018. PMID: 30080247 Free PMC article.
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands.
Kersting S, Neppelenbroek SIM, Visser HPJ, van Gelder M, Levin MD, Mous R, Posthuma W, van der Straaten HM, Kater AP. Kersting S, et al. Among authors: mous r. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):52-57. doi: 10.1016/j.clml.2017.09.015. Epub 2017 Sep 25. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29097160
Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction.
Mous R, Jaspers A, Luijks DM, Mellink CH, van Oers MH, Kater AP, Eldering E. Mous R, et al. Leukemia. 2009 Jul;23(7):1352-5. doi: 10.1038/leu.2009.71. Epub 2009 Apr 2. Leukemia. 2009. PMID: 19340003 No abstract available.
Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.
Jak M, Mous R, Remmerswaal EB, Spijker R, Jaspers A, Yagüe A, Eldering E, Van Lier RA, Van Oers MH. Jak M, et al. Among authors: mous r. Leuk Lymphoma. 2009 May;50(5):788-801. doi: 10.1080/10428190902803677. Leuk Lymphoma. 2009. PMID: 19452318
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback